BRIEF—NorthSea Therapeutics raises $40 million

Dutch liver specialist NorthSea Therapeutics has raised $40 million in a series B financing round, funding development of a treatment for non-alcoholic steatohepatitis (NASH).

New US investor venBio Partners led the round, and the firm’s principal, Richard Gaster, will join the board at NorthSea.

Lead candidate icosabutate is in the Phase IIb dose ranging ICONA study. The firm is targeting a Phase I study in the second half of 2020 for its second program, SEFA-1024, for dyslipidaemia.